| Literature DB >> 27117317 |
Youn Jeong Kim1, Jun Hee Woo2, Min Ja Kim3, Dae Won Park3, Joon-Young Song3, Shin Woo Kim4, Jun Yong Choi5, June Myung Kim5, Sang Hoon Han5, Jin-Soo Lee6, Bo Youl Choi7, Joo Shil Lee8, Sung-Soon Kim8, Mee-Kyung Kee8, Moon Won Kang1, Sang Il Kim1.
Abstract
BACKGROUND/AIMS: The frequencies of opportunistic diseases (ODs) vary across countries based on genetic, environmental, and social differences. The Korean HIV/AIDS cohort study was initiated in 2006 to promote research on human immunodeficiency virus (HIV) infection in Korea, and to provide a logistical network to support multicenter projects on epidemiological, clinical, and laboratory aspects of HIV infection. This study evaluated the prevalence of ODs among HIV-infected patients in the era of highly active antiretroviral therapy, and the risk factors associated with ODs.Entities:
Keywords: AIDS-related opportunistic infections; HIV; Korea; Tuberculosis
Mesh:
Year: 2016 PMID: 27117317 PMCID: PMC5016273 DOI: 10.3904/kjim.2014.322
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Comparisons of demographic characteristics between patients with ODs and without ODs
| Characteristic | Total (n = 1,086) | ODs (+) (n = 297) | ODs (–) (n = 789) | |
|---|---|---|---|---|
| Age, yr | 41 (33–50) | 44 (36–52) | 41 (32–50) | < 0.01 |
| Male sex | 1,007 (92.7) | 279 (93.9) | 728 (92.3) | 0.37 |
| Transmission route | ||||
| Sexual contact | 945 (97.0)[ | 261 (87.8)[ | 684 (86.7)[ | 0.89 |
| Transfusion or blood product | 24 (2.5)[ | 9 (3.0)[ | 15 (1.9)[ | 0.87 |
| Injection drug use | 5 (0.5)[ | 3 (1.0)[ | 2 (0.3)[ | 0.09 |
| Vertical transmission | 0 | 0 | 0 | - |
| CD4 T cell count at enrollment, cell/mm3 | 352 (207–514) | 240 (111–395) | 388 (254–560) | < 0.01 |
| CD4 T cell at HIV diagnosis, cell/mm3 | 237 (93–377) | 75 (25–203) | 279.5 (169–420) | < 0.01 |
| Viral load at enrollment, log copies/mL | 5.69 (3.88–6.24) | 5.04 (4.17–5.56) | 4.57 (3.8–6.09) | 0.62 |
| HARRT at enrollment | 730 (67.3) | 232 (78.1) | 498 (63.1) | < 0.01 |
| Body mass index, kg/m2 | 21.5 (19.4–23.5) | 21.1 (19–23.5) | 21.6 (19.8–23.6) | 0.77 |
| Smoking | ||||
| Current | 465 (71.5)[ | 111 (59.4) | 354 (76.5) | < 0.01 |
| Former | 648 (68.0)[ | 189 (70.0) | 459 (67.2) | 0.40 |
| Alcohol | ||||
| Current | 483 (73.0)[ | 106 (57.9) | 377 (78.7) | < 0.01 |
| Former | 656 (70.0)[ | 183 (68.3) | 473 (70.0) | 0.47 |
| Tuberculosis history | 196 (18.0) | 115 (38.7) | 81 (10.2) | < 0.01 |
| Hypertension | 112 (10.3) | 29 (9.7) | 83 (10.5) | 0.84 |
| Diabetes mellitus | 71 (6.5) | 17 (5.7) | 54 (6.8) | 0.38 |
| Previous BCG history | 377 (54.5)[ | 108 (36.4) | 269 (34.1) | 0.71 |
Values are presented as median (interquartile range) or number (%).
OD, opportunistic disease; HIV, human immunodeficiency; HARRT, highly active antiretroviral therapy; BCG, Bacillus Calmette-Guérin.
This data included only on that complete a questionnaire.
Distribution of opportunistic disease and CD4 T cell count
| Variable | No. of cases | CD4 T cell, cell/mm3 |
|---|---|---|
| Candidiasis | 176 (16.2) | |
| Oral candidiasis | 120 | 49 (17–133) |
| Esophageal candidiasis | 54 | 43 (19–95.5) |
| Respiratory candidiasis | 2 | - |
| Tuberculosis | 120 (11.0) | 87 (37–205) |
| Nontuberculous Mycobacteria infection | 2 (0.2) | - |
| 121 (11.1) | 30 (11–68) | |
| CMV infection | 52 (4.7) | 25.5 (12.75–101.5) |
| Retinitis | 19 | |
| Pneumonia | 13 | |
| Hepatitis | 9 | |
| Colitis | 2 | |
| Cytomegalovirus viremia | 9 | |
| Herpes zoster | 44 (4.0) | 185 (116.5–273.5) |
| Herpes simplex virus infection | 8 (0.7) | 128 (10–320) |
| Recurrent pneumonia | 7 (0.7) | 62.5 (12–170) |
| Progressive multifocal leukoencephalopathy | 6 (0.6) | 107 (64.25–154) |
| Cryptococcosis | 6 (0.6) | 31.2 (9.5–76.75) |
| Toxoplasmosis | 4 (0.4) | 107 (25.5–246.25) |
| Isosporiasis | 1 (0.09) | - |
| Non-Hodgkin’s lymphoma | 4 (0.4) | 128 (26–222.5) |
| Burkitt lymphoma | 1 | |
| Diffuse large B-cell lymphoma | 3 | |
| Kaposi’s sarcoma | 8 (0.7) | 133 (28–269) |
| Cervical carcinoma | 1 (0.09) | - |
Values are presented as number (%) or median (interquartile range).
Figure 1.Distribution of CD4 cell count in study patients with opportunistic disease. PCP, Pneumocystis carinii pneumonia; CMV, cytomegalovirus.
Risk factors for opportunistic disease among HIV patients
| Factor | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age | 0.98 | 0.96–0.99 | < 0.01 | 0.98 | 0.95–1.01 | 0.29 |
| Body mass index | 1.01 | 0.98–1.02 | 0.77 | |||
| CD4 T cell, HIV diagnosis | 1.01 | 1.01–1.05 | < 0.01 | 1.01 | 1.03–1.07 | < 0.01 |
| Viral load at enrollment | 1 | 0.90–1.02 | 0.67 | |||
| CD4 T cell at enrollment | 1.01 | 1.02–1.04 | < 0.01 | 1.001 | 1.01–1.03 | 0.45 |
| HAART at enrollment | 2.47 | 1.79–3.41 | < 0.01 | 1.41 | 0.55–3.56 | 0.47 |
| Current smoking | 2.22 | 1.55–3.19 | < 0.01 | 2.27 | 1.22–4.26 | 0.01 |
| Current alcohol | 2.68 | 1.86–3.87 | < 0.01 | 2.57 | 1.34–4.91 | 0.04 |
| Tuberculosis history | 5.61 | 4.03–7.7 | < 0.01 | 5.23 | 2.69–10.2 | < 0.01 |
HIV, human immunodeficiency; OR, odds ratio; CI, confidence interval; HAART, highly active antiretroviral therapy.